PF-06648671

• UNSPSC Description:

  PF-06648671?is a novel, brain-penetrable, and orally active γ-secretase modulator (GSM). PF-06648671 reduces Aβ42 and Aβ40, with concomitant increases in Aβ37 and Aβ38 in vitro. PF-06648671 is used for the study of Alzheimer’s disease[1].

• Target Antigen:

  γ-secretase

• Type:

  Reference compound

• Related Pathways:

  Neuronal Signaling;Stem Cell/Wnt

• Field of Research:

  Neurological Disease

• Assay Protocol:

  https://www.medchemexpress.com/pf-06648671.html

• Purity:

  98.12

• Solubility:

  DMSO : 125 mg/mL (ultrasonic)

• Smiles:

  FC(F)(C(C=C1Cl)=C([C@](CC2)([H])O[C@]2([H])[C@@H](N(CCN3C4=CC=C(N5C=NC(C)=C5)C3=O)C4=O)C)C=C1F)F

• Molecular Weight:

  538.92

• References & Citations:

  [1]Jae Eun Ahn, et al. Pharmacokinetic and Pharmacodynamic Effects of a γ-Secretase Modulator, PF-06648671, on CSF Amyloid-β Peptides in Randomized Phase I Studies. Clin Pharmacol Ther 2020 Jan;107(1):211-220.

• Shipping Conditions:

  Blue Ice

• Storage Conditions:

  -20°C, 3 years (Powder)

• Clinical Information:

  Phase 1

• CAS Number:

  1587727-31-8